Sébastien Groyer

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.